Compare

Essity AB/Skr ESSITY B

1D1W1M3M6MYTD1Y5YMAX

About Essity AB

Essity AB is a global hygiene and health company headquartered in Stockholm, Sweden. The company operates in the industry of hygiene and health products, providing essentials such as tissue paper, baby diapers, feminine care products, incontinence products, and medical solutions. With a wide range of offerings segmented into Personal Care, Consumer Tissue, and Professional Hygiene, Essity serves both consumer and business markets. The company traces its origins back to the hygiene business of SCA, from which it was spun off in 2017. Essity is known for its strong market positions in Europe and significant presence in Asia, Latin America, and North America, capitalizing on a diverse brand portfolio and scale of operations to maintain competitive advantage.
Ticker
Skr ESSITY B
Primary listing
XSTO
Employees
36,000
Headquarters
Stockholm, Sweden

Essity AB Metrics

BasicAdvanced
kr 192B
17.40
kr 16.34
0.39
kr 8.75
3.08%

What the Analysts think about Essity AB

Analyst ratings (Buy, Hold, Sell) for Essity AB stock.
Analyst projections of the future price of Essity AB stock.

Bulls say / Bears say

Essity is gaining ground in higher-value categories: incontinence and feminine care grew with market-share gains, while Health & Medical saw growth in wound care. This mix could support better growth and profitability over time. (Essity)
Cash generation held up despite a difficult quarter, with operating cash flow rising to SEK 5.8bn from SEK 5.3bn a year earlier. Cost savings were delivered to plan, giving Essity some capacity to invest and absorb pressure. (Essity)
The planned Brazilian feminine-care acquisition adds leading brands and a business with about SEK 1.4bn in annual sales and good profitability. It expands Essity in a category and market the company sees as attractive, though closing is expected only in 2027. (Essity)
Organic sales fell 0.3% in the third quarter, while the adjusted EBITA margin dropped to 13.1% from 14.6% a year earlier. Weakness in Consumer Tissue and Professional Hygiene raises doubts about near-term sales momentum. (Essity)
Higher raw-material, energy and distribution costs are eroding profitability faster than pricing can offset them: the adjusted margin fell and management expects costs of goods sold to rise further in the fourth quarter. That leaves recovery dependent on price increases and savings taking effect. (Essity, Investing.com)
A sale or separation of Consumer Tissue could be costly to execute because the unit shares operations with other businesses. UBS estimates a full divestment could leave SEK 3.5bn–6.5bn of stranded costs, with the full benefits potentially taking until around 2030. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Nov 2026.

Essity AB Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Essity AB Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing Essity AB

AllEURUSD
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.